Active safety surveillance of rabies monoclonal antibody and rabies vaccine in patients with category III potential rabies exposure

BACKGROUND: A vero cell-based inactivated Rabies Vaccine (Rabivax-S) and Rabies Human Monoclonal Antibody (Rabishield) have been approved since 2016. A post-marketing surveillance was conducted in India from 2020 to 2021 to gather real world safety data on Rabivax-S and Rabishield. METHODS: This was...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Gagandeep, Lakhkar, Anand, Bhamare, Chetanraj, Dharmadhikari, Abhijeet, Narwadkar, Jyoti, Kanujia, Arti, Kapse, Dhananjay, Gunale, Bhagwat, Poonawalla, Cyrus S., Kulkarni, Prasad S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10363514/
https://www.ncbi.nlm.nih.gov/pubmed/37492421
http://dx.doi.org/10.1016/j.lansea.2023.100207

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10363514/
https://www.ncbi.nlm.nih.gov/pubmed/37492421
http://dx.doi.org/10.1016/j.lansea.2023.100207

Ejemplares similares